Home / Research library / Semaglutide
Semaglutide: molecular data, studies & sources
Semaglutide is catalogued here as a research compound. This profile brings together the molecular source record, selected indexed publications and available supplier comparisons. Evidence for a named substance does not authenticate a commercial product.
Compiled by PeptideTech Editors · Sources checked · Selected bibliography, not a systematic review
Molecular formula, weight & structure
- Molecular formula (MF)
- C187H291N45O59
- Molecular weight (MW)
- 4114 g/mol
- PubChem compound ID
- 56843331
- Record title
- Semaglutide
Values describe the selected PubChem molecular entity. Counterions, salt forms, hydration and sequence changes can alter the supplied material. Confirm the exact identity against the supplier specification.
Source: PubChem CID 56843331 · retrieved 2026-09-21

Chemical identifiers and source data
- IUPAC name
- 18-[[(1R)-4-[2-[2-[2-[2-[2-[2-[[(5S)-5-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]-2-methylpropanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-5-oxopentanoyl]amino]propanoyl]amino]propanoyl]amino]-6-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[[2-[[(2S)-5-carbamimidamido-1-(carboxymethylamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-6-oxohexyl]amino]-2-oxoethoxy]ethoxy]ethylamino]-2-oxoethoxy]ethoxy]ethylamino]-1-carboxy-4-oxobutyl]amino]-18-oxooctadecanoic acid
- InChIKey
- DLSWIYLPEUIQAV-CCUURXOWSA-N
- SMILES
- CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@H](C(=O)O)NC(=O)CCCCCCCCCCCCCCCCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC6=CN=CN6)N
Human and clinical studies
Selected human-study records are shown with their indexed or reviewed study type. Check the original article for the intervention, formulation and controls; the molecule can also be a comparator or measured variable.
- Human study · PubMed trial index
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.
Garvey WT, Blüher M, Osorto Contreras CK et al. · The New England journal of medicine · 2025
PMID 40544433 · DOI: 10.1056/NEJMoa2502081
- Human study · PubMed trial index
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.
Wilding JPH, Batterham RL, Davies M et al. · Diabetes, obesity & metabolism · 2022
PMID 35441470 · DOI: 10.1111/dom.14725
- Human study · PubMed trial index
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Marso SP, Bain SC, Consoli A et al. · The New England journal of medicine · 2016
PMID 27633186 · DOI: 10.1056/NEJMoa1607141
- Human study · PubMed trial index
Once-Weekly Semaglutide in Adults with Overweight or Obesity.
Wilding JPH, Batterham RL, Calanna S et al. · The New England journal of medicine · 2021
PMID 33567185 · DOI: 10.1056/NEJMoa2032183
- Human study · PubMed trial index
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.
Rubino D, Abrahamsson N, Davies M et al. · JAMA · 2021
PMID 33755728 · DOI: 10.1001/jama.2021.3224
Preclinical research, reviews & other publications
Animal studies, laboratory experiments, reviews and other indexed papers answer different questions. A review is secondary evidence; a case report does not estimate how often an outcome occurs.
- Review · secondary evidence
Safety of Semaglutide.
Smits MM, Van Raalte DH · Frontiers in endocrinology · 2021
PMID 34305810 · DOI: 10.3389/fendo.2021.645563
- Review · secondary evidence
Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis.
Tan HC, Dampil OA, Marquez MM et al. · Journal of the ASEAN Federation of Endocrine Societies · 2022
PMID 36578889 · DOI: 10.15605/jafes.037.02.14
- Preclinical / laboratory research
Semaglutide lowers body weight in rodents via distributed neural pathways.
Gabery S, Salinas CG, Paulsen SJ et al. · JCI insight · 2020
PMID 32213703 · DOI: 10.1172/jci.insight.133429
Semaglutide supplier sources
Scientific sources describe molecules and experiments. The commercial links below identify recorded supplier packages. A publication or chemical database entry does not verify the seller, purity, sterility or contents of a lot. Some links are affiliate links; see our disclosure.
Compare all Semaglutide sizes, forms and supplier prices →
| Supplier | Recorded packages | Example source listing |
|---|---|---|
| American PeptidesUSD | 5mg Vial · 10mg Vial · 20mg Vial3 recorded offers | 5mg Vial · $60.00Recorded out of stock · Checked Sep 21, 2026Supplier listing |
| Modified AminosUSD | 10mg Vial1 recorded offers | 10mg Vial · $49.99Checked Sep 16, 2026Supplier listing |
| Blank PeptidesUSD | 10mg Vial1 recorded offers | 10mg Vial · $79.00Checked Sep 21, 2026Supplier listing |
| Amino ClubUSD | 10mg Vial1 recorded offers | 10mg Vial · $49.99Checked Sep 16, 2026Supplier listing |
| Direct PeptidesUSD | 5mg Vial · 10mg Vial2 recorded offers | 5mg Vial · $49.00Checked Sep 16, 2026Supplier listing |
| PeptiLabCAD | 30mg Vial · 20mg Vial · 10mg Vial3 recorded offers | 30mg Vial · CA$220.00Checked Sep 17, 2026Supplier listing |
| Nuvion PeptidesCAD | 10mg Vial · 30mg Vial2 recorded offers | 10mg Vial · CA$89.99Checked Sep 21, 2026Supplier listing |
Reference sources & further reading
- PubChem compound record 56843331 — chemical identity and structure.
- Wikipedia: Semaglutide — Background encyclopedia; not a primary clinical source.
The citations above link directly to publication records. Encyclopedia links are background reading and are not used to establish clinical effectiveness.
Search for additional research
These links run searches; their results have not been individually reviewed and can include unrelated compounds.
Research information is not a dosing guide or a recommendation for personal use. Study findings are specific to the formulation, population and methods tested. Read our source and correction policy.
Related research profiles
Cagrilintide
C194H312N54O59S2
4409 g/mol · PubChem CID 171397054
5 selected publications · 4 human study records
Liraglutide
C172H265N43O51
3751 g/mol · PubChem CID 16134956
7 selected publications · 5 human study records
Mazdutide
C207H317N45O65
4476 g/mol · PubChem CID 167312357
6 selected publications · 5 human study records
Retatrutide
C221H342N46O68
4731 g/mol · PubChem CID 171390338
8 selected publications · 6 human study records
Survodutide
C192H289N47O61
4232 g/mol · PubChem CID 168429725
5 selected publications · 5 human study records
Tirzepatide
C225H348N48O68
4813 g/mol · PubChem CID 156588324
8 selected publications · 7 human study records